Please Wait.....
Report
Gastrointestinal Stromal Tumor (GIST) - Epidemiology Forecast - 2032
Market Report I 2022-08-01 I 100 Pages I DelveInsight
DelveInsight's Gastrointestinal Stromal Tumor (GIST)- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Gastrointestinal Stromal Tumor (GIST), historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor (GIST) trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Gastrointestinal Stromal Tumor (GIST) Disease Understanding
As per GIST Support International, gastrointestinal stromal tumor (GIST) is rare cancer affecting the digestive tract or nearby structures within the abdomen. It is a sarcoma that arises either from cells called interstitial cells of Cajal (ICCs) or from less differentiated stem cells or precursor cells that can develop into ICCs.
GIST progression is driven by mutations in KIT or PDGFRA or by other rare gene alterations, all of which are mutually exclusive. It is known that the majority of tumors of GIST will have mutations in the KIT gene, and a minority, in the PDGFR gene.
Wild-type GIST do not have mutations of the KIT or PDGFR genes. Some of the cases of wild-type GIST have been linked to genes involved in the succinate dehydrogenase (SDH) enzyme complex (i.e., SDHA, SDHB, SDHC, or SDHD genes). Additional genes have been linked to wild-type GIST, includes BRAF, KRAS, and NRAS mutations.
Gastrointestinal Stromal Tumor (GIST) Diagnosis
A GIST diagnosis is typically made or ruled out based on a patient's medical history, a comprehensive physical examination, and the results of a series of tests. The testing methods used to confirm or rule out a GIST can vary based on a patient's symptoms and other individual factors.
After physical examination, CT scan (CAT scan), MRI, Endoscopic ultrasound, biopsy, Immunohistochemistry, Mitotic rate, PET scan can be performed to confirm the disease and its severity.
Continued in the report..
Gastrointestinal Stromal Tumor (GIST) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total incident cases of GIST, Gender-specific Incident Cases of GIST, Age-specific Incident Cases of GIST, Incident Cases of GIST by Mutation, and Stage-specific Incident Cases of GIST in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2032.
Gastrointestinal Stromal Tumor (GIST) Detailed Epidemiology Segmentation
- In the assessment done by DelveInsight, the estimated total incident cases of GIST in the 7MM were 14,251 in 2021.
- The highest incident cases of GIST were accounted by the US in 2021 (6,035 cases), which are expected to show a steep rise soon due to the improvement in diagnostic testing and advancements in genetic testing and accounts for 42% of the total cases in the 7MM.
- In 2021, the age-specific incident cases of GIST accounted highest in the age group 66-80 years with 5,384 cases in the 7MM, followed by age group 51-65 years with 4,581 cases. While the least number of cases were seen in the age group 0-17 years.
- Among the European countries, Germany had the highest incident population of GIST with 1,736 cases, followed by Italy, which had incident population of 1,095 in 2021. On the other hand, Spain had the lowest incident population (824 cases).
- Japan had 2,458 incident cases for GIST in 2021, accounting for approximately 17% of total incident cases in the 7MM.
Scope of the Report
- The report covers the descriptive overview of Gastrointestinal Stromal Tumor (GIST), explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden of Gastrointestinal Stromal Tumor (GIST).
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
Report Highlights
- 11-Year Forecast of Gastrointestinal Stromal Tumor (GIST)
- 7MM Coverage
- Total Incident Cases of GIST
- Gender-specific Incident Cases of GIST
- Age-specific Incident Cases of GIST
- Mutation-specific Incident Cases of GIST
- Stage-specific Incident Cases of GIST
Key Questions Answered
- What are the disease risk and burden of Gastrointestinal Stromal Tumor (GIST)?
- What is the historical Gastrointestinal Stromal Tumor (GIST) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Gastrointestinal Stromal Tumor (GIST) at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Gastrointestinal Stromal Tumor (GIST)?
- Out of the above-mentioned countries, which country would have the highest incident population of Gastrointestinal Stromal Tumor (GIST) during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to buy
The Gastrointestinal Stromal Tumor (GIST) report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM Gastrointestinal Stromal Tumor (GIST) epidemiology forecast.
- The Gastrointestinal Stromal Tumor (GIST) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The Gastrointestinal Stromal Tumor (GIST) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
1. Key Insights
2. Report Introduction
3. Gastrointestinal Stromal Tumor Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of GIST in 2019
3.2. Patient Share (%) Distribution of GIST in 2032
4. Gastrointestinal Stromal Tumor: Future Perspective
5. Executive Summary of Gastrointestinal Stromal Tumors
6. Patient Journey
7. Gastrointestinal Stromal Tumor: Disease Background and Overview
7.1. Introduction of Gastrointestinal Stromal Tumor
7.2. Etiology of Gastrointestinal Stromal Tumor
7.3. Signs and Symptoms of Gastrointestinal Stromal Tumor
7.4. Risk Factors of Gastrointestinal Stromal Tumor
7.5. Classification of Gastrointestinal Stromal Tumor Based on Mutations
7.6. Pathophysiology of Gastrointestinal Stromal Tumor
7.7. Pathogenesis of Gastrointestinal Stromal Tumor
7.8. Genetic Background of Gastrointestinal Stromal Tumor
7.9. Biomarkers Associated With Gastrointestinal Stromal Tumor
7.10. Diagnosis of Gastrointestinal Stromal Tumor
7.10.1. Diagnostic Guidelines of Gastrointestinal Stromal Tumor
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Epidemiology Methodology
8.3. Assumptions and Rationale: Seven Major Market
8.3.1. The United States
8.3.2. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
8.3.3. Japan
8.4. Total Incident Cases of Gastrointestinal Stromal Tumor in the 7MM
8.5. The United States
8.5.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.5.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.5.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.5.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.5.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
8.6.1. Germany
8.6.1.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.6.1.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.1.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.1.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.1.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST)
8.6.2. France
8.6.2.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.6.2.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.2.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.2.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.2.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST)
8.6.3. Italy
8.6.3.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.6.3.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.3.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.3.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.3.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST)
8.6.4. Spain
8.6.4.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.6.4.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.4.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.4.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.4.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.5. The United Kingdom
8.6.5.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.6.5.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.5.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.5.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.5.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST)
8.7. Japan
8.7.1. Total Incident Cases of Gastrointestinal Stromal Tumor in Japan
8.7.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan
8.7.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan
8.7.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan
8.7.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan
9. Key Opinion Leaders' Views
10. Appendix
10.1. Bibliography
10.2. Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight
Table 1: Summary of Gastrointestinal Stromal Tumor Epidemiology (2019-2032)
Table 2: Key Events
Table 3: Diagnosis of GIST
Table 4: Total Incident Cases of Gastrointestinal Stromal Tumor in the 7MM (2019-2032)
Table 5: Total Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Table 6: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Table 7: Age-specific Incident of Gastrointestinal Stromal Tumor in the US (2019-2032)
Table 8: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Table 9: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Table 10: Total Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Table 11: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Table 12: Age-specific Incident of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Table 13: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Table 14: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Table 15: Total Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Table 16: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Table 17: Age-specific Incident of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Table 18: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Table 19: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Table 20: Total Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Table 21: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Table 22: Age-specific Incident of Gastrointestinal Stromal Tumor in France (2019-2032)
Table 23: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Table 24: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Table 25: Total Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Table 26: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Table 27: Age-specific Incident of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Table 28: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Table 29: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Table 30: Total Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Table 31: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Table 32: Age-specific Incident of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Table 33: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Table 34: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Table 35: Total Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Table 36: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Table 37: Age-specific Incident of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Table 38: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Table 39: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Table 40: Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Table 41: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Table 42: Age-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Table 43: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Table 44: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Figure 1: Signs and Symptoms of Gastrointestinal Stromal Tumor (GIST)
Figure 2: Primary GIST Anatomic Locations and Relative Frequencies
Figure 3: Classification of Gastrointestinal Stromal Tumor (GIST)
Figure 4: The Structure of the KIT Receptor Tyrosine Kinase
Figure 5: KIT Gain-of-function Mutations in GISTs
Figure 6: KIT and PDGFRA Cell Signaling Pathways
Figure 7: KIT and PDGFRA Receptor Tyrosine Kinases with Location and Relative Frequencies of Mutations
Figure 8: Genetic and Cytogenetic changes Associated with Progression of Gastrointestinal Stromal Tumor
Figure 9: Total Incident Cases of Gastrointestinal Stromal Tumor in the 7MM (2019-2032)
Figure 10: Total Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Figure 11: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Figure 12: Age-specific Incident of Gastrointestinal Stromal Tumor in the US (2019-2032)
Figure 13: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Figure 14: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Figure 15: Total Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Figure 16: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Figure 17: Age-specific Incident of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Figure 18: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Figure 19: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Figure 20: Total Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Figure 21: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Figure 22: Age-specific Incident of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Figure 23: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Figure 24: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Figure 25: Total Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Figure 26: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Figure 27: Age-specific Incident of Gastrointestinal Stromal Tumor in France (2019-2032)
Figure 28: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Figure 29: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Figure 30: Total Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Figure 31: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Figure 32: Age-specific Incident of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Figure 33: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Figure 34: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Figure 35: Total Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Figure 36: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Figure 37: Age-specific Incident of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Figure 38: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Figure 39: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Figure 40: Total Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Figure 41: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Figure 42: Age-specific Incident of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Figure 43: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Figure 44: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Figure 45: Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Figure 46: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Figure 47: Age-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Figure 48: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Figure 49: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security